Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 21783417

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2011 Aug
First author
Zhou C

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2011 Aug;12(8):710-1. doi: 10.1016/S1470-2045(11)70194-2.
    note
    Source null
    related pmid
    21783418
    relationship
    Comment in

Authors and identifiers

  1. name
    Zhou C
    type
    Author
  2. name
    Wu YL
    type
    Author
  3. name
    Chen G
    type
    Author
  4. name
    Feng J
    type
    Author
  5. name
    Liu XQ
    type
    Author
  6. name
    Wang C
    type
    Author
  7. name
    Zhang S
    type
    Author
  8. name
    Wang J
    type
    Author
  9. name
    Zhou S
    type
    Author
  10. name
    Ren S
    type
    Author
  11. name
    Lu S
    type
    Author
  12. name
    Zhang L
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Zhou C
    type
    Author
  2. name
    Wu YL
    type
    Author
  3. name
    Chen G
    type
    Author
  4. name
    Feng J
    type
    Author
  5. name
    Liu XQ
    type
    Author
  6. name
    Wang C
    type
    Author
  7. name
    Zhang S
    type
    Author
  8. name
    Wang J
    type
    Author
  9. name
    Zhou S
    type
    Author
  10. name
    Ren S
    type
    Author
  11. name
    Lu S
    type
    Author
  12. name
    Zhang L
    type
    Author
bibliography ids
  1. nci-bib-01c19d0edc73c326a05f99c8
book metadata
content sha256
a694926ede2c6ba6ee99bef20e662d78757dc265eae431d20fb8cf2e671fc6e7
document type
citation
dois
  1. 10.1016/S1470-2045(11)70184-X
electronic publication date
display
2011 Jul 23
precision
day
year
2011
evidence scope
bibliographic_metadata_only
id
pubmed:21783417
immutable id
pubmed:21783417@a694926ede2c6ba6ee99bef20e662d78757dc265eae431d20fb8cf2e671fc6e7
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
8
name
The Lancet. Oncology
nlm unique id
100957246
pages
735-42
volume
12
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2011 Aug;12(8):710-1. doi: 10.1016/S1470-2045(11)70194-2.
    note
    Source null
    related pmid
    21783418
    relationship
    Comment in
outcomes validated
false
pmid
21783417
provenance
batch id
2529ef2eca926738ab13
provider
NCBI PubMed ESummary
record sha256
4f882f6c6df25263ea77315b47629dfdaca840df1f6f9ee517a135432a8b914c
response sha256
9204e3dd8d67df5a6773613a8059d8d42d9842ee24eecc9b0f39a62f636c99b6
retrieved at
2026-09-09T23:46:42.856296+00:00
publication date
display
2011 Aug
precision
month
year
2011
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/21783417/
title
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Preserved source evidence · Not medical advice